Alimera Sciences (NASDAQ:ALIM) released its earnings results on Wednesday. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.03) by ($0.07), Yahoo Finance reports. The firm had revenue of $9.14 million for the quarter, compared to analysts’ expectations of $9.60 million.
Alimera Sciences (NASDAQ ALIM) traded up $0.06 on Thursday, reaching $1.30. 170,900 shares of the company traded hands, compared to its average volume of 142,872. The company has a market cap of $85.74, a P/E ratio of -4.19 and a beta of 1.79. Alimera Sciences has a 52 week low of $1.03 and a 52 week high of $1.72. The company has a debt-to-equity ratio of -0.71, a quick ratio of 4.65 and a current ratio of 4.84.
ALIM has been the subject of a number of research reports. Zacks Investment Research downgraded shares of Alimera Sciences from a “hold” rating to a “sell” rating in a research report on Monday, November 27th. HC Wainwright reissued a “buy” rating and set a $5.00 target price on shares of Alimera Sciences in a research report on Monday, January 22nd. Cowen reissued a “buy” rating on shares of Alimera Sciences in a research report on Thursday, November 2nd. Finally, ValuEngine raised shares of Alimera Sciences from a “strong sell” rating to a “sell” rating in a research report on Monday, November 27th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. Alimera Sciences has an average rating of “Hold” and an average price target of $3.38.
ILLEGAL ACTIVITY WARNING: “Alimera Sciences (ALIM) Releases Earnings Results, Misses Estimates By $0.07 EPS” was first reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this article on another site, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The correct version of this article can be viewed at https://www.tickerreport.com/banking-finance/3231407/alimera-sciences-alim-releases-earnings-results-misses-estimates-by-0-07-eps.html.
About Alimera Sciences
Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.
Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.